Diffusion Pharmaceuticals (NASDAQ:DFFN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Diffusion Pharmaceuticals in a research note on Thursday, April 7th.

Shares of DFFN stock opened at $0.24 on Monday. The stock has a 50-day simple moving average of $0.26 and a 200 day simple moving average of $0.34. Diffusion Pharmaceuticals has a fifty-two week low of $0.20 and a fifty-two week high of $0.86. The stock has a market capitalization of $24.64 million, a P/E ratio of -0.93 and a beta of 1.46.

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Diffusion Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 858,408 shares of the company’s stock valued at $437,000 after purchasing an additional 54,118 shares during the period. Renaissance Technologies LLC boosted its position in shares of Diffusion Pharmaceuticals by 8.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,223,102 shares of the company’s stock valued at $373,000 after purchasing an additional 97,600 shares during the period. Citadel Advisors LLC acquired a new position in shares of Diffusion Pharmaceuticals in the 2nd quarter valued at $110,000. Finally, Virtu Financial LLC acquired a new position in shares of Diffusion Pharmaceuticals in the 4th quarter valued at $46,000. 9.09% of the stock is owned by institutional investors and hedge funds.

Diffusion Pharmaceuticals Company Profile (Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor.

Further Reading